Daiichi Sankyo Generics Entry Could Help Japan's Branded Generics Makers
This article was originally published in PharmAsia News
Executive Summary
Following Pfizer's step, Daiichi Sankyo is venturing into the generic drug business in Japan. The third-largest domestic branded drug maker Feb. 26 announced the establishment of generic subsidiary Daiichi Sankyo Espha, and a plan to start marketing products beginning in October. The announcement has stirred up a shock wave across the industry